ABT-737
目录号:S1002 Purity: 99.98%
ABT-737是一种BH3模拟抑制剂,作用于Bcl-xL,Bcl-2和Bcl-w,无细胞试验中EC50分别为78.7 nM,30.3 nM和197.8 nM;但对Mcl-1, Bcl-B及Bfl-1没有抑制作用。ABT-737可诱导线粒体通路的凋亡和线粒体自噬。Phase 2。
CAS: 852808-04-9
客户使用Selleck的ABT-737发表文献372篇
- Immunity, 2024 S1074-7613(24)00492-8
- Gastroenterology, 2024 S0016-5085(24)00062-3
- Nat Neurosci, 2023 26(5):737-750
- Cancer Cell, 2022 S1535-6108(22)00312-9
- Signal Transduct Target Ther, 2022 7(1):51
- Blood, 2022 blood.2021014304
- Science, 2021 371(6535)eabc5386
- J Infect, 2021 S0163-4453(21)00200-0
- Cancer Discov, 2020 CD-20-0756
- Am J Respir Crit Care Med, 2019 200(1):84-97
- Cell, 2018 175(2):429-441
- Cancer Cell, 2018 33(3):435-449
- Immunity, 2018 48(4):675-687
- Nature, 2017 551(7679):247-250
- Nat Methods, 2017 14(9):891-896
- Nat Cell Biol, 2017 19(10):1226-1236
- Nat Cell Biol, 2017 19(9):1116-1129
- Nature, 2016 529(7586):413-417
- Blood, 2015 24;126(13):1565-74
- Nat Med, 2013 19(11):1478-88
- Mol Cancer, 2013 12(1):42
- Blood, 2012 120(19):3978-85
- Nat Biotechnol, 2011 29(6):542-6
- Blood, 2011 117(26):7145-54
- Nat Commun, 2024 15(1):830
- Nat Commun, 2024 15(1):1041
- Nucleic Acids Res, 2024 gkae322
- Cell Death Differ, 2024 10.1038/s41418-024-01301-w
- Leukemia, 2024 38(1):136-148
- Cell Death Dis, 2024 15(9):677
- Biomacromolecules, 2024 10.1021/acs.biomac.4c00672
- Int J Mol Sci, 2024 25(9)4864
- Biomolecules, 2024 14(5)555
- Oncol Rep, 2024 52(3)122
- Exp Gerontol, 2024 186:112359
- PLoS One, 2024 19(9):e0309533
- Vet Microbiol, 2024 298:110298
- Cell Mol Life Sci, 2023 80(10):311
- EMBO Rep, 2023 e55536.
- Int J Cancer, 2023 152(11):2321-2330
- Cells, 2023 12(11)1474
- Cells, 2023 10.3390/cells12182247
- Cancer Cell Int, 2023 23(1):49
- Mol Cancer Ther, 2023 22(1):135-149
- Int J Mol Sci, 2023 24(8)7180
- Cancers -Basel), 2023 15(19)4772
- Sci Rep, 2023 13(1):1221
- Biology (Basel), 2023 12(7)988
- Wound Repair Regen, 2023 31(5):613-626.
- Front Aging, 2023 4:1258836
- Nat Commun, 2022 13(1):6977
- Nat Chem Biol, 2022 10.1038/s41589-022-00996-7
- Cell Death Differ, 2022 10.1038/s41418-022-00995-0
- Dev Cell, 2022 S1534-5807(22)00306-9
- J Exp Clin Cancer Res, 2022 41(1):340
- ACS Appl Mater Interfaces, 2022 10.1021/acsami.1c22138
- J Eur Acad Dermatol Venereol, 2022 10.1111/jdv.18051
- Cell Death Dis, 2022 13-9:787
- Cell Rep, 2022 39(9):110879
- Biomed Pharmacother, 2022 150:113034
- Ecotoxicol Environ Saf, 2022 234:113395
- Cells, 2022 11(5)794
- Int J Mol Sci, 2022 23(22)14170
- Aging (Albany NY), 2022 14(3):1068-1086
- Aging (Albany NY), 2022 14(16):6381-6414
- Cancers (Basel), 2022 14(19)4710
- Biomedicines, 2022 10(7)1552
- J Pharmacol Exp Ther, 2022 381(2):164-175
- Invest New Drugs, 2022 10.1007/s10637-022-01297-5
- Edinburgh Research Archive, 2022 10.7488/era/2944
- Cell Death Dis, 2021 12(8):736
- Cell Death Dis, 2021 12(11):1011
- Cell Death Dis, 2021 12(8):784
- Blood Adv, 2021 5(17):3497-3510
- Antioxidants (Basel), 2021 10(6)956
- Commun Biol, 2021 4(1):20
- Int J Mol Sci, 2021 22(10)5405
- Adv Biol Regul, 2021 S2212-4926(20)30091-9
- Frontiers in-Molecular Biosciences, 2020- Volume 7
- ACS Nano, 2020 14(3):3378-3388
- Nat Commun, 2020 11(1):259
- Cell Death Differ, 2020 10.1038
- EMBO J, 2020 e105071
- Cancer Res, 2020 10.1158/0008-5472.CAN-19-1784
- Cell Death Dis, 2020 11(1):8
- Cell Rep, 2020 32(1):107845
- Elife, 2020 2;9:e54954
- Biomed Pharmacother, 2020 126:110040
- Cancer Cell Int, 2020 20:405
- Mol Cancer Ther, 2020 5;molcanther.510.2019
- Aging (Albany NY), 2020 12(14):14174-14188
- Cancers (Basel), 2020 10;12(2) pii: E406
- Mol Cancer Res, 2020 10.1158/1541-7786.MCR-19-0669
- Front Mol Biosci, 2020 7:566291
- Ann Transl Med, 2020 8(6):364
- Sci Rep, 2020 20;10(1):687
- Eur J Pharm Sci, 2020 142:105105
- Development, 2020 147(22)dev194555
- Environ Toxicol, 2020 10.1002
- Life Sci Alliance, 2020 28;3(6) pii: e202000735
- Allergy Asthma Immunol Res, 2020 12(4):608-625
- PLoS One, 2020 15(7):e0234103
- Platelets, 2020 10.1080/09537104.2020.1724276
- Infect Immun, 2020 10.1128/IAI.00851-19
- Transfusion, 2020 60(4):806-814
- Sci Adv, 2020 6(34):eaba8968
- Sci Adv, 2020 6(47)eabc3465
- STAR Protoc, 2020 1(1)100034
- Nat Commun, 2019 10(1):5770
- Mol Cell, 2019 74(1):19-31
- Dev Cell, 2019 51(2):277-291
- EMBO J, 2019 15;38(10):e101638
- EMBO J, 2019 38(11)
- Cancer Res, 2019 79(9):2339-2351
- Cell Death Dis, 2019 10(2):121
- Cell Rep, 2019 27(12):3657-3671
- Cell Rep, 2019 27(3):820-834
- Phytomedicine, 2019 64:153068
- Phytomedicine, 2019 52:147-156
- Elife, 2019 8e38730
- Oxid Med Cell Longev, 2019 2019:5820415
- Br J Pharmacol, 2019 176(3):436-450
- Thromb Haemost, 2019 19(10):1665-1674
- Life Sci, 2019 232:116561
- Eur J Immunol, 2019 10.1002/eji.201948254
- Oncotarget, 2019 10(58):6219-6233
- Cancers (Basel), 2019 11(9)
- Cancers (Basel), 2019 11(12)
- Chem Biol Interact, 2019 309:108723
- Sci Rep, 2019 9(1):1897
- Biochem J, 2019 476(9):1335-1357
- Onco Targets Ther, 2019 12:897-906
- J Cancer, 2019 10(6):1466-1478
- PLoS One, 2019 14(12):e0225977
- Mol Pharmacol, 2019 96(4):419-429
- J Bone Oncol, 2019 19:100268
- J Bone Oncol, 2019 15:100222
- Platelets, 2019 30(1):75-80
- Nat Commun, 2018 9(1):5435
- Cell Death Differ, 2018 25(4):784-796
- Clin Cancer Res, 2018 24(21):5458-5470
- Cell Death Dis, 2018 9(10):944
- Cell Death Dis, 2018 9(2):123
- Cell Death Dis, 2018 9(10):994
- Cell Death Dis, 2018 9(2):199
- Cell Death Dis, 2018 92(10)
- Oncogene, 2018 37(39):5325-5339
- Oncogene, 2018 37(33):4599-4610
- Cell Mol Life Sci, 2018 75(14):2663-2680
- Thromb Res, 2018 171:22-30
- Phytother Res, 2018 32(6):1126-1134
- Antioxidants (Basel), 2018 10.3390/antiox7110150
- Eur J Med Chem, 2018 159:357-380
- Oncotarget, 2018 9(28):20075-20088
- Oncotarget, 2018 9(24):16701-16717
- Oncotarget, 2018 9(2):2384-2394
- Oncotarget, 2018 9(39):25630-25646
- Oncotarget, 2018 9(42):26834-26851
- Int J Oncol, 2018 53(3):1055-1068
- Mol Cancer Res, 2018 16(6):935-946
- Cancers (Basel), 2018 10(11)E439
- Biochim Biophys Acta Mol Cell Res, 2018 1865(3):522-531
- Sci Rep, 2018 8(1):15752
- Cell Physiol Biochem, 2018 48(3):1123-1138
- Cancer Biol Ther, 2018 19(6):465-474
- Environ Mol Mutagen, 2018 59(1):49-59
- Ann Surg Treat Res, 2018 95(5):240-248
- Nat Commun, 2017 8:16078
- J Clin Invest, 2017 127(1):153-168
- J Clin Invest, 2017 127(2):635-650
- J Allergy Clin Immunol, 2017 140(2):418-430
- Biomaterials, 2017 144:73-83
- Cell Death Differ, 2017 24(11):1963-1974
- Cancer Res, 2017 77(9):2512-2521
- Proc Natl Acad Sci U S A, 2017 114(6):E980-E989
- Genes Dev, 2017 31(17):1754-1769
- Cancer Lett, 2017 411:19-26
- Cell Death Dis, 2017 8(6):e2898
- Clin Immunol, 2017 181:32-42
- Oncogene, 2017 36(15):2066-2073
- Elife, 2017 6e22509
- Elife, 2017 6
- Elife, 2017 6
- Sci Signal, 2017 10(499)
- Thromb Haemost, 2017 117(2):311-324
- Arch Toxicol, 2017 91(5):2191-2208
- Biochem Pharmacol, 2017 140:41-52
- Mol Cancer Ther, 2017 16(1):102-115
- Eur J Immunol, 2017 47(6):1009-1021
- Oncotarget, 2017 8(65):108522-108533
- Oncotarget, 2017 8(63):107206-107222
- Oncotarget, 2017 8(43):74299-74311
- Oncotarget, 2017 8(29):46801-46817
- Oncotarget, 2017 8(5):8670-8678
- Mol Cell Biol, 2017 37(3)e00535-16
- J Biol Chem, 2017 292(36):15105-15120
- Viruses, 2017 9(10)
- Mol Cell Biochem, 2017 429(1-2):91-102
- Analyst, 2017 142(23):4399-4404
- Toxicol In Vitro, 2017 42:38-46
- Arch Oral Biol, 2017 73:1-6
- Oncol Lett, 2017 14(1):903-908
- Asia Pac J Clin Oncol, 2017 13(2):e144-e152
- Anat Rec (Hoboken), 2017 300(2):326-339
- Tumour Biol, 2017 39(3):1010428317695965
- Nat Commun, 2016 7:11190
- J Clin Invest, 2016 126(1):181-94
- Autophagy, 2016 12(7):1083-93
- Clin Cancer Res, 2016 22(5):1138-49
- Cancer Res, 2016 76(6):1313-9
- Cell Death Dis, 2016 7(8):e2342
- Br J Cancer, 2016 114(11):1219-26
- Br J Pharmacol, 2016 173(3):471-83
- Oncogenesis, 2016 10.1038/oncsis.2016.33
- Cancer Cell Int, 2016 16:27
- J Virol, 2016 90(5):2356-71
- Oncotarget, 2016 7(50):83208-83222
- Oncotarget, 2016 7(3):3520-32
- Oncotarget, 2016 7(51):85492-85501
- Oncotarget, 2016 7(6):6626-38
- Oncotarget, 2016 7(24):35989-36001
- Oncotarget, 2016 7(48):79637-79653
- Oncotarget, 2016 7(51):84594-84607
- Oncotarget, 2016 7(47):77815-77824
- Am J Cancer Res, 2016 6(6):1345-57
- Lab Invest, 2016 96(10):1128-37
- Biochim Biophys Acta, 2016 1863(4):562-71
- Mol Ther Methods Clin Dev, 2016 3:16003
- Sci Rep, 2016 6:21264
- Cell Cycle, 2016 15(12):1531-7
- J Immunother, 2016 39(3):117-26
- Biochem Biophys Res Commun, 2016 477(4):607-13
- Biochem Biophys Res Commun, 2016 478(1):143-148
- Exp Ther Med, 2016 11(2):669-673
- Anticancer Res, 2016 36(4):1673-82
- Tumour Biol, 2016 37(8):10839-49
- Nat Commun, 2015 6:6891
- Autophagy, 2015 11(3):452-9
- Cell Death Differ, 2015 10.1038/cdd.2015.8
- Clin Cancer Res, 2015 21(17):3995-4003
- Cancer Res, 2015 75(24):5318-28
- Cancer Res, 2015
- Proc Natl Acad Sci U S A, 2015 112(6):E536-45
- Cell Death Dis, 2015 6:e1989
- EMBO Rep, 2015 16(5):618-27
- J Med Chem, 2015 58(4):1644-68
- Mol Oncol, 2015 9(2):409-21
- Cancer Cell Int, 2015 15:34
- Oncotarget, 2015 6(26):22624-40
- Oncotarget, 2015 6(34):36338-53
- Oncotarget, 2015 6(8):5582-96
- Oncotarget, 2015 6(14):12405-20
- Oncotarget, 2015 6(34):35667-83
- Oncotarget, 2015 6(1):409-26
- Int J Oncol, 2015 46(2):667-76
- J Biol Chem, 2015 290(19):12290-9
- J Biol Chem, 2015 290(34):20841-55
- Eur J Pharm Sci, 2015 70:64-71
- Hepatol Res, 2015 45(9):1023-1033
- BMC Cancer, 2015 15:919
- PLoS One, 2015 10(11):e0143685
- Exp Cell Res, 2015 335(1):62-7
- Exp Cell Res, 2015 10.1016/j.yexcr.2015.04.016
- Cell Biochem Funct, 2015 33(5):334-40
- Neurogastroenterol Motil, 2015 10.1111/nmo.12521
- Chembiochem, 2015 16(5):757-65
- Biochem Biophys Res Commun, 2015 464(1):286-91
- Exp Hematol, 2015 43(3):180-190.e6
- Anticancer Res, 2015 35(3):1803-8
- Anticancer Res, 2015
- Arch Pharm Chem Life Sci, 2015 348: 1-11
- Nat Commun, 2014 5:5637
- Biomaterials, 2014 16(2):R41
- Autophagy, 2014 10(10):1776-86
- Cell Death Differ, 2014 21(7):1170-7
- Cell Death Differ, 2014 10.1038/cdd.2014.158
- Clin Cancer Res, 2014 20(21):5446-55
- Leukemia, 2014 28(10):1960-8
- Cancer Lett, 2014 10.1016/j.canlet.2014.09.024
- Cancer Lett, 2014 348(1-2):38-49
- Cell Death Dis, 2014 5:e1514
- Cell Death Dis, 2014 5(10):e1445
- Cell Death Dis, 2014 5:e1291
- Cell Death Dis, 2014 5:e1275
- Cell Rep, 2014 7(6):1887-99
- Thromb Res, 2014 134(6):1311-5
- Thromb Res, 2014 133(1):73-9
- Sci Signal, 2014 7(357):ra122
- Acta Neuropathol Commun, 2014 10.1186/2051-5960-2-57
- Biomater Sci, 2014 2(9):1186-1194
- Mol Cancer Ther, 2014 10.1158/1535-7163.MCT-13-0998
- Int J Mol Sci, 2014 15(11):20500-17
- Mol Cancer Res, 2014 13(12):3332-42
- Mol Cancer Res, 2014 (4):550-9
- J Biol Chem, 2014 289(22):15495-15506
- J Immunol, 2014 193(10):4914-23
- Bone, 2014 67:166-74
- J Immunother, 2014 37(1):8-15
- PLoS One, 2014 9(1):e84388
- PLoS One, 2014 9(9):e103015
- PLoS One, 2014 9(9):e106571
- PLoS One, 2014 9(2):e88587
- PLoS One, 2014 9(8):e105049
- PLoS One, 2014 9(3):e91782
- PLoS One, 2014 9(5):e96733
- Biomed Res Int, 2014 2014:306718
- Int J Cardiol, 2014 176(3):923-9
- Int J Hyperthermia, 2014 30(7):502-12
- Leuk Lymphoma, 2014 5:1-12
- Cell Death Differ, 2013 20(11):1532-45
- Proc Natl Acad Sci U S A, 2013 110(11):4321-6
- Cell Death Dis, 2013 4:e690
- Cell Death Dis, 2013 4:e702
- Cell Death Dis, 2013 4:e931
- Cell Death Dis, 2013 4:e801
- Cell Death Dis, 2013 4:e762
- Cell Death Dis, 2013 4:e742
- Br J Cancer, 2013 108(9):1870-8
- Biomed Pharmacother, 2013 67(7):583-91
- Apoptosis, 2013 18(11):1403-15
- Br J Haematol, 2013 163(3):377-84
- Br J Haematol, 2013 161(2):245-54
- Int J Cancer, 2013 133(8):1813-24
- Cancer Gene Ther, 2013 20(7):386-93
- Stem Cells Transl Med, 2013 2(9):690-702
- Cancer Sci, 2013 104(6):732-9
- Oncotarget, 2013
- J Neurosci, 2013 33(46):18098-108
- Mol Cancer Res, 2013 11(2):109-21
- J Biol Chem, 2013 288(10):6826-34
- J Ovarian Res, 2013 6(1):72
- Int J Biochem Cell Biol, 2013 45(5):944-51
- Toxicol Appl Pharmacol, 2013 274(2):319-27
- PLoS One, 2013 8(11):e78570
- Cytometry A, 2013 83(2):227-34
- PLoS One, 2013 8(5):e63232
- Exp Dermatol, 2013 22(8):518-23
- Basic Clin Pharmacol Toxicol, 2013 113(3):145-51
- Biochem Biophys Res Commun, 2013 437(4):565-72
- Leuk Lymphoma, 2013 54(2):372-80
- Phys Biol, 2013 10(3):035002
- Mol Cell, 2012 46(5):573-83
- J Clin Invest, 2012 122(6):2018-31
- EMBO J, 2012 31(10):2322-35
- Oncogene, 2012 31(26):3177-89
- Anal Chem, 2012 84(11):4703-10
- Breast Cancer Res, 2012 14(3):R96
- Phytother Res, 2012 27(6):835-40
- Br J Haematol, 2012 159(5):565-71
- Mol Cancer Res, 2012 10(3):347-59
- J Biol Chem, 2012 287(25):21357-70
- J Biol Chem, 2012 287(21):17682-92
- Mol Endocrinol, 2012 26(9):1508-20
- BMC Cancer, 2012 12:541
- PLoS One, 2012 7(8):e43158
- PLoS One, 2012 7(12):e52333
- J Pharmacol Sci, 2012 119(4):330-40
- Neuro Oncol, 2011 13(12):1265-76
- J Clin Invest, 2011 121(3):1053-63
- Leukemia, 2011 25(11):1728-38
- Cancer Res, 2011 71(13):4494-505
- Oncogene, 2011 30(37):3918-29
- Am J Nephrol, 2011 34(6):549-59
- PLoS One, 2011 6(6):e20423
- PLoS One, 2011 6(9):e24102
- Biochem Biophys Res Commun, 2011 408(2):344-9
- Cancer Chemoth Pharm, 2011 67(3):557-67
- Curr Pharmacogenomics Person Med, 2011 9(3):184-190
- Apoptosis, 2010 15(10):1256-69
- Mol Cancer Ther, 2010 19(20):5591-601
- J Biol Chem, 2010 285(26):19910-20
- Exp Hematol, 2010 38(10):908-921
化学信息&溶解度
分子量 | 813.43 |
分子式 | C42H45ClN6O5S2 |
CAS号 | 852808-04-9 |
Smiles | CN(C)CCC(CSC1=CC=CC=C1)NC2=C(C=C(C=C2)S(=O)(=O)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)CC5=CC=CC=C5C6=CC=C(C=C6)Cl)[N+](=O)[O-] |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 100 mg/mL ( 122.93 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 100 mg/mL ( 122.93 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 163 mg/mL ( 200.38 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 100 mg/mL ( 122.93 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
2%DMSO
40%PEG300
5%Tween80
53%ddH2O
浓度:2mg/ml
(2.46mM)
操作示例:以 1 mL 工作液为例,取20μL100mg/ml的澄清DMSO储备液加到 400μLPEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入530μLddH2O定容至 1 mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。